BSA
DGX icon

Braun Stacey Associates’s Quest Diagnostics DGX Stock Holding History

Braun Stacey Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7M Sell
154,396
-2,436
-2% -$478K 0.93% 39
2026
Q1 		$30.7M Buy
156,832
+2,978
+2% +$579K 1.02% 30
2025
Q4 		$26.7M Sell
153,854
-515
-0.3% -$93.8K 0.87% 41
2025
Q3 		$29.4M Buy
154,369
+18,417
+14% +$3.27M 0.96% 31
2025
Q2 		$24.4M Buy
+135,952
New +$23.6M 0.88% 45

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Braun Stacey Associates's DGX Position: Q2 2026 in Review

Braun Stacey Associates reduced its Quest Diagnostics (DGX) stake by 1.6% in Q2 2026, selling an estimated $478K and leaving 154,396 shares worth $32.7M. The position accounts for 0.93% of the portfolio, ranked #39.

Braun Stacey Associates first reported a position in DGX in Q2 2025 and has held it in 5 quarters since. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Braun Stacey Associates held 154,396 shares of Quest Diagnostics worth $32.7M as of Q2 2026.
  • Braun Stacey Associates sold 2,436 Quest Diagnostics shares in Q2 2026, an estimated $478K.
  • Quest Diagnostics made up 0.93% of Braun Stacey Associates's portfolio in Q2 2026, its #39 holding.
  • Braun Stacey Associates first reported a position in Quest Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Braun Stacey Associates's 13F filing for Q2 2026, filed 5 Aug 2026.